Not provided
Not provided
Not provided
Not provided
Not provided
The investigation of this device has been transitioned into a new study by the sponsor. The data generated in this study will not be used to support a marketing application
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Connected Catheter is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization. It is a sterile, extended-use device that resides fully internally to the male lower urinary tract for an intended use life of up to 7 days per catheter.
Spinal Singularity has developed the Connected Catheter System to address several drawbacks of urinary catheters. The Connected Catheter is fully internal, indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization. Each subject will use the Connected Catheter for up to 35-40 days. This includes five device exchange appointments. The appointments are spaced 7 days apart and at each appointment the catheter will be replaced with a new one. Additionally, weekly follow-up will occur for 14 days following the final appointment after the subject discontinues use of study device and reverts to his original catheter.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Connected Catheter Users | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Connected Urinary Catheter | Device | Patients will use the Connected Catheter to empty the bladder during the course of treatment. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Successful Bladder Emptying Using Connected Catheter | Rate of participants with successful voiding using the Connected Catheter as assessed by Post-Residual Volume (PVR) measurement via ultrasound A subject is considered a responder to the treatment if a minimum of 80% of their PVR values met the following criteria PVR is ≤ 50 mL OR PVR is ≤ baseline PVR with the standard of care catheter | 35-40 days |
| Rate of device related Serious Adverse Events | Rate of participants treated with the Connected Catheter reported with a serious device related adverse event | 0 - 40 days |
| Measure | Description | Time Frame |
|---|---|---|
| Successful device insertion, anchoring, and removal | Rate of Connected Catheter successfully inserted, anchored and removed | 35-40 days |
| Successful sealing of the catheter valve | Rate of Connected Catheter valves sealed successfully |
Not provided
Inclusion Criteria:
Males age ≥ 18 with clinical diagnosis of significant urinary retention
Must be clinically suitable and capable of safely managing bladder using an intermittent voiding or indwelling strategy
Must have stable urinary management history as determined by the Investigator
OR:
Must have urodynamic profile suitable for the Gen 2 Connected Catheter (including bladder capacity > 200mL without uninhibited bladder contractions)
Subject's lower urinary tract anatomy must fall within the ranges serviceable by the Gen 2 Connected Catheter device, as specified in the Investigational Device Instructions for use (IFU)
Exclusion Criteria:
Active symptomatic urinary tract infection (UTI), as defined in this protocol (subjects may receive the device after UTI has been treated)
Significant risk profile or recent history of urethral stricture (e.g. stricture within past 90 days)
Significant risk profile or recent history of clinically significant (uncontrolled) autonomic dysreflexia (AD)
Significant intermittent urinary incontinence (between catheterizations)
Uninhibited bladder contractions and/or Vesicoureteral reflux that is not reliably controlled with medication or alternate therapy (e.g. Botox injections)
Pre-existing urinary pathologies and/or morphological abnormalities of the lower urinary tract or bladder (assessed during in-depth medical screening, including cystoscopy and urine analysis)
Dependence on an electro-magnetic medical implant (e.g. cardiac pacemaker or implanted drug pump) or external device
Any unsuitable comorbidities as determined by the investigator or complications related to use of certain medications
Any physical or cognitive impairments that diminish the subject's ability to follow directions or otherwise safely use the Connected Catheter System
Catheter Assessment Tool screening yields unacceptable results
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| West Coast Urology, 11411 Brookshire Avenue, Suite 508 | Downey | California | 90241 | United States | ||
| West Coast Urology, 575 E. Hardy St., Suite 215 |
Not provided
| ID | Term |
|---|---|
| D016055 | Urinary Retention |
| D001750 | Urinary Bladder, Neurogenic |
| D014570 | Urologic Diseases |
| D013119 | Spinal Cord Injuries |
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D014555 | Urination Disorders |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 35-40 days |
| Quality of life improvement as measured by SCI-QOL Survey and other surveys | Rate of participants treated with the Connected Catheter with improved overall quality of life as measured by the SCI-QOL Survey and other surveys | 35-40 days |
| UTI occurrence rate | Rate of participants treated with the Connected Catheter reported with a urinary tract infection | 35-40 days |
| Lower Urinary Tract injury rate | Rate of participants treated with the Connected Catheter that experience a lower urinary tract injury | 35-40 days |
| Inglewood |
| California |
| 90301 |
| United States |
| Tri Valley Urology, 25495 Medical Center Dr., Suite 204 | Murrieta | California | 92562 | United States |
| Chesapeake Urology | Owings Mills | Maryland | 21117 | United States |
| Minnesota Urology, 6025 Lake Road Suite 200 | Woodbury | Minnesota | 55125 | United States |
| New Jersey Urology, 15000 Midlantic Drive, Suite 100 | Mount Laurel | New Jersey | 08054 | United States |
| New Jersey Urology, 2401 Evesham Road, Suite F | Voorhees Township | New Jersey | 08043 | United States |
| Dr. Jonathan Vapnek Urology | New York | New York | 10075 | United States |
| Urology San Antonio | San Antonio | Texas | 78229 | United States |
| D052801 | Male Urogenital Diseases |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001745 | Urinary Bladder Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D020196 | Trauma, Nervous System |
| D014947 | Wounds and Injuries |
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D011469 | Prostatic Diseases |